Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets

• Published in: American journal of hematology Vol. 95; no. 4; pp. 379 - 386
• Main Authors: Hauschner, Hagit, Bokstad Horev, Melanie, Misgav, Modi, Nagar, Meital, Seligsohn, Uri, Rosenberg, Nurit, Koren‐Michowitz, Maya
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.04.2020; Wiley Subscription Services, Inc
• Subjects: Adenosine Diphosphate - pharmacology; Adherent cells; Adult; Blood Platelets - drug effects; Calcium (intracellular); Calcium - blood; Calreticulin; Calreticulin - genetics; Cell Shape; Female; Fibrinogen; Flow cytometry; Hematology; Humans; Janus kinase 2; Janus Kinase 2 - genetics; Leukocytes - pathology; Localization; Male; Microscopy, Interference; Middle Aged; Mutation; Mutation, Missense; P-Selectin - blood; PAC1 protein; Platelet Activation - drug effects; Platelets; Receptors, Thrombopoietin - metabolism; Thrombocythemia, Essential - blood; Thrombocythemia, Essential - complications; Thrombocythemia, Essential - genetics; Thrombomodulin - blood; Thrombophilia - etiology; Thrombophilia - genetics; Thrombosis

Both JAK2V617F and calreticulin (CALR) mutated essential thrombocythemia (ET) patients have different clinical characteristics, with lower thrombosis risk in patients with CALR mutations. To elucidate the mechanism for this lower risk we studied platelet function in ET patients with either JAK2V617F...